Compass Pathways PLC Sponsored ADR (NASDAQ:CMPS) Given Average Recommendation of “Moderate Buy” by Brokerages

Compass Pathways PLC Sponsored ADR (NASDAQ:CMPS) has earned a consensus recommendation of “Moderate Buy” from the nine analysts that are currently covering the stock, MarketBeat.com reports. One analyst has rated the stock with a sell rating, one has issued a hold rating, six have issued a buy rating and one has issued a strong buy rating on the company. The average 1 year price target among analysts that have issued a report on the stock in the last year is $22.1250.

A number of research analysts have issued reports on the company. Royal Bank Of Canada lifted their target price on Compass Pathways from $21.00 to $22.00 and gave the company an “outperform” rating in a research report on Wednesday, February 18th. Canaccord Genuity Group increased their target price on shares of Compass Pathways from $15.00 to $20.00 and gave the stock a “buy” rating in a report on Wednesday, February 18th. Compass Point set a $15.00 price target on shares of Compass Pathways in a research note on Thursday, February 12th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Compass Pathways in a report on Wednesday, January 21st. Finally, Lifesci Capital upgraded shares of Compass Pathways to a “strong-buy” rating in a research report on Thursday, February 12th.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of CMPS. Persistent Asset Partners Ltd bought a new position in shares of Compass Pathways in the 4th quarter valued at $38,000. Advisory Services Network LLC bought a new stake in Compass Pathways during the 3rd quarter worth $41,000. Caitong International Asset Management Co. Ltd acquired a new position in Compass Pathways in the 4th quarter worth about $47,000. China Universal Asset Management Co. Ltd. increased its holdings in Compass Pathways by 46.7% in the 2nd quarter. China Universal Asset Management Co. Ltd. now owns 18,272 shares of the company’s stock worth $51,000 after purchasing an additional 5,817 shares in the last quarter. Finally, BIT Capital GmbH bought a new position in Compass Pathways in the third quarter valued at about $54,000. 46.19% of the stock is currently owned by institutional investors and hedge funds.

Compass Pathways Price Performance

Compass Pathways stock opened at $6.39 on Friday. The company has a debt-to-equity ratio of 0.55, a quick ratio of 1.23 and a current ratio of 1.23. Compass Pathways has a 52 week low of $2.25 and a 52 week high of $8.90. The stock has a market capitalization of $613.55 million, a P/E ratio of -2.35 and a beta of 1.90. The stock has a fifty day moving average of $6.99 and a 200-day moving average of $6.24.

Compass Pathways Company Profile

Compass Pathways (NASDAQ: CMPS) is a clinical-stage biotechnology company focused on the development and commercialization of psilocybin therapy for mental health disorders. Founded in 2016 and headquartered in London with additional offices in the United States, Compass Pathways is pioneering the use of synthetic psilocybin combined with psychotherapy to address treatment-resistant depression. The company’s flagship program is a Phase IIb clinical trial evaluating COMP360, its proprietary psilocybin formulation, which has received Breakthrough Therapy designation from the U.S.